TITLE

Questions about donepezil

PUB. DATE
April 1998
SOURCE
CMAJ: Canadian Medical Association Journal;04/21/98, Vol. 158 Issue 8, p1014
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
24708126

 

Related Articles

  • Combination of Risperidone and Donepezil in Lewy Body Dementia. Geizer, M.; Ancill, R. J. // Canadian Journal of Psychiatry;May1998, Vol. 43 Issue 4, p421 

    A letter to the editor is presented in response to the article which talks about the combination of risperidone and donepezil in Lewy Body dementia.

  • Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate Alzheimer's disease. Standridge, John B. // Evidence Based Mental Health;Nov2004, Vol. 7 Issue 4, p112 

    The article presents an answer to the clinical question related to the effect of donepezil in people with mild to moderate Alzheimer's disease. The superiority, typically in cognition, of donepezil and other cholinesterase inhibitors (ChEls) to placebo has been confirmed in a systematic review....

  • The Authors Reply. Wilcock, Gordon; Howe, Ian; Coles, Hilary; Lilienfeld, Sean; Truyen, Luc; Young Zhu, Luc; Bullock, Roger // Drugs & Aging;2003, Vol. 20 Issue 15, p1140 

    Presents a response by Gordon Wilcock and colleagues to a letter to the editor about their article "A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease".

  • Which treatments are effective for cognitive, behavioural and psychological symptoms in dementia? Warner, James P.; Mrcpsych, Rob Butler; Prabhakaran, Pramod // Evidence Based Mental Health;Aug2003, Vol. 6 Issue 3, p69 

    This article gives an insight about treatments which are effective for cognitive, behavioral and psychological symptoms in dementia. It has been found that donepezil drug compared with placebo improves cognitive function and global clinical state at up to 52 weeks in people with mild to moderate...

  • Donepezil: A Review of its Use in Alzheimer's Disease. Dooley, M.; Lamb, H.M. // Drugs & Aging;2000, Vol. 16 Issue 3, p199 

    Donepezil (E-2020) is a reversible, noncompetitive, piperidine-type cholinesterase inhibitor. It is selective for acetylcholinesterase rather than butyrylcholinesterase. Donepezil 5 and 10 mg/day significantly improved cognition and global clinical function compared with placebo in well designed...

  • Reply. López-Pousa, Secundino; Garre-Olmo, Josep; Vilalta-Franch, Joan // Age & Ageing;Mar2007, Vol. 36 Issue 2, p235 

    A response by Secundino López-Pousa and colleagues to a letter to the editor about their article "Comparative Analysis of Mortality in Patients With Alzheimer's Disease Treated With Donepezil and Galantamine" in the 2006 issue of "Age and Ageing" is presented.

  • Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment. Petersen, Ronald C.; Thomas, Ronald G.; Thal, Leon J. // New England Journal of Medicine;9/1/2005, Vol. 353 Issue 9, p951 

    A response by researcher Ronald C. Petersen and his colleagues to a letter to the editor about their article on the use of Vitamin E and Donepezil for the treatment of mild cognitive impairment in the June 9, 2005 issue is presented.

  • Better Pilots through Chemistry? Goyer, Robert // Flying;Feb2003, Vol. 130 Issue 2, p31 

    Reports on the impact of the Alzheimer's drug donepezil on pilot performance. Details about the study; Performance of pilots after the administration of the drug; Retention of training on complex aviation tasks; Issues on aircraft flying by pilots.

  • Effects of Cognitive-Communication Stimulation for Alzheimer's Disease Patients Treated With Donepezil. Chapman, Sandra Bond; Weiner, Myron F.; Rackley, Audette; Hynan, Linda S.; Zientz, Jennifer // Journal of Speech, Language & Hearing Research;Oct2004, Vol. 47 Issue 5, p1149 

    This randomized study evaluated the combined effect of a cognitive-communication program plus an acetylcholinesterase inhibitor (donepezil; donepezil-plusstimulation group; n = 26), as compared with donepezil alone (donepezil-only group; n = 28) in 54 patients with mild to moderate Alzheimer's...

  • VIOLENT BEHAVIOR ASSOCIATED WITH ACETYLCHOLINESTERASE INHIBITORS AND LIABILITY OF PRESCRIBERS OF DONEPEZIL. Brewer, Janet // Widener Law Journal;2006, Vol. 16 Issue 1, p111 

    The article examines the exact nature and mechanism of action of acetylcholinesterase inhibitors and their propensity to mediate aggressive responses. It investigates the duty to warn of side effects induced by acetylcholinesterase inhibitors. It concludes that while the manufacturer of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics